Benign fibrous histiocytoma arising from the right shoulder: Is immunohistochemical staining always required for a definitive diagnosis?  by Akbulut, Sami et al.
B
i
S
D
a
A
R
R
A
A
K
B
D
C
C
1
e
h
c
s
o
i
B
b
m
a
i
4
t
t
2
dCASE  REPORT  –  OPEN  ACCESS
International Journal of Surgery Case Reports 3 (2012) 287– 289
Contents lists available at SciVerse ScienceDirect
International  Journal  of  Surgery  Case  Reports
j ourna l ho me page: www.elsev ier .com/ locate / i j scr
enign  ﬁbrous  histiocytoma  arising  from  the  right  shoulder:  Is
mmunohistochemical  staining  always  required  for  a  deﬁnitive  diagnosis?
ami  Akbulut ∗, Zulfu  Arikanoglu, Murat  Basbug
epartment of Surgery, Diyarbakir Education and Research Hospital, Diyarbakir 21400, Turkey
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 16 December 2011
eceived in revised form 29 February 2012
ccepted 12 March 2012
vailable online 24 March 2012
eywords:
enign ﬁbrous histiocytoma
ermatoﬁbrosarcoma protuberans
D34
D68
a  b  s  t  r  a  c  t
INTRODUCTION:  Fibrous  histiocytomas  are  divided  into  two  subgroups:  malignant  and  benign  ﬁbrous
histiocytomas  (BFHs).  BFH  is one  of the  most  common  tumors  of the  superﬁcial  and  deep  soft  tissues;  it
is  commonly  found  on  the  skin  and  presents  as  a  slow-growing  solitary  nodule  made  up  of  a  mixture  of
ﬁbroblastic  and  histiocytic  cells.
PRESENTATION OF  CASE:  In  this  study,  we present  the  case  of  a 45-year-old  female  who  was  histopatho-
logically  diagnosed  with  dermatoﬁbrosarcoma  protuberans  (DFSP)  and  received  radiotherapy,  but  whose
diagnosis  was  changed  to BFH  based  on  subsequent  immunohistochemical  analyses.
DISCUSSION: BFH is  a  mesenchymal  soft-tissue  tumor  with  ﬁbroblastic  and  histiocytic  differentiation.
Differential  diagnosis  for  BFH  found  in  deeper  tissues  includes  other  aggressive  ﬁbrohistiocytic  lesions,
such  as  DFSP  and  malignant  ﬁbrous  histiocytoma.  Differentiating  among  these  tumors  is  crucial  in  select-
ing  the  correct  surgical  strategy  and  patient  management  in  the  postoperative  period.  In most  cases,  the
pleomorphism  and  atypical  mitotic  activity  seen  histopathologically  are  sufﬁcient  for  the  differentiation
between  benign  and  malignant  tumors.  Immunohistochemical  staining  methods  should  be used  in  cases
that  are  difﬁcult  to  diagnose.  The  treatment  of choice  for  BFH  is  wide  resection  of  the  tumor,  which  results
in  an  excellent  prognosis  and  low  recurrence  rate.  In  agreement  with  cases  reported  in the  literature,  our
case  conﬁrms  that wide  excision  is  adequate  to  prevent  the  recurrence  of  the tumor.
CONCLUSION: Although  benign  ﬁbrous  histiocytomas  is  rare, it must  be considered  in  the differential
diagnosis  of  tumors  arising  from  the soft-tissue.
gical .© 2012 Sur
. Introduction
A  benign ﬁbrous histiocytoma (BFH; dermatoﬁbroma) is a mes-
nchymal tumor of soft tissues characterized by ﬁbroblastic and
istiocytic differentiation. Although the soft tissue in the dermis
onstitutes the predominant origination site, the tumor may  also
tem from subcutaneous tissue, bone, and, rarely, parenchymal
rgans in <1–2% of cases.1–4 Establishing a deﬁnitive diagnosis
s straightforward in tumors located in the dermis; however, a
FH originating from the deep subcutaneous tissues can frequently
e confused with dermatoﬁbrosarcoma protuberans (DFSP) and
alignant ﬁbrous histiocytoma (MFH). Recently, the differentiation
mong these tumors has been improved with immunohistochem-
cal staining methods. In this study, we present the case of a
5-year-old female patient who was diagnosed with DFSP and
herefore received radiotherapy, but whose diagnosis was  changed
o BFH based on subsequent immunohistochemical analyses.∗ Corresponding author. Tel.: +90 412 2580050; fax: +90 412 2580052.
E-mail  address: akbulutsami@gmail.com (S. Akbulut).
210-2612     ©  2012 Surgical Associates Ltd. Published by Elsevier Ltd. 
oi:10.1016/j.ijscr.2012.03.006
Open access under CC Associates Ltd. Published by Elsevier Ltd. 
2. Case presentation
A  45-year-old female was  admitted to our clinic with the
complaint of a progressively growing pruritic lump on her right
shoulder. The patient stated that the mass had been present in that
position for about 15 years, but had grown and become pruritic in
the previous 2 months. The patient’s medical history revealed no
prior surgery or systemic illness. Physical examination revealed a
crusted, 3 cm × 2.5 cm,  brownish-red mass with a nodular growth
pattern protruding from the skin of the posterior right shoulder. A
plain chest X-ray, blood biochemistry, and other blood parameters
yielded no pathological ﬁnding; therefore, the mass was excised
with a 1-cm-wide margin of excision under local anesthesia. The
mass was sectioned and stained using hematoxylin and eosin (H&E)
and Van Gieson’s stain for connective tissue. Histopathologic exam-
ination revealed that the lateral margins of the excised material
were clear, but a tumor with fusiform cells arranged in a storiform
pattern consistent with a DFSP was located within the collage-
nous stroma and exhibited continuity with the deep-seated surgical
margins. As a result, a second surgery was performed to extend the
Open access under CC BY-NC-ND licenselateral wide margins to 3 cm and include the muscular fascia in
the deep surgical margins. The surgical defect was reconstructed
with a Limberg ﬂap (Fig. 1). The pathology report documented the
tumor as a DFSP with clear surgical margins. Following recovery,
 BY-NC-ND license.
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dig. 1. View of the tumoral alanine excised with a Limberg ﬂap in the post-
econstruction  period. The red lines show the area in which radiotherapy was
pplied.
he patient was referred to the medical and radiation oncology
epartment. While no medical treatment was administered to the
atient during the postoperative period, she did receive radio-
herapy (50-Gy total dose, 2-Gy daily fractional doses). Positron
mission tomography-computed tomography (PET-CT) performed
sing 18F-ﬂuorodeoxyglucose (FDG) at the end of the ﬁrst postop-
rative year revealed no pathological FDG uptake. No recurrence
as observed during a 22-month follow-up period. After reevalu-
ting the pathology preparations retrospectively, we decided that
mmunohistochemical reevaluation would be appropriate and sent
he specimens to another center for further examination. The
econd pathology report stated that the ﬁbroblastic cells were
rranged histopathologically in a storiform pattern; immunohis-
ochemical staining revealed positivity for CD68 and negativity for
D34, which was consistent with the diagnosis of a BFH (Fig. 2).
.  Discussion
Fibrous histiocytomas (FHs) are divided into benign and malig-
ant subgroups. MFHs typically arise as rapidly growing masses
n the soft tissues of the extremities and bones in patients aged
0–70 years. First deﬁned by Dahlin4 in 1978, BFHs are soft-tissue
ig. 2. Histiocytic cells stained positively with diffuse CD68 (200× immunoperoxi-
ase).PEN  ACCESS
rgery Case Reports 3 (2012) 287– 289
tumors characterized by tumoral differentiation of ﬁbroblasts and
histiocytes with an unknown etiology; they frequently stem from
the dermis or superﬁcial subcutaneous tissues. BFH is one of the
most common types of soft-tissue tumors and is most frequently
found in middle-aged adults, with a slight predilection for females.
Although the upper extremities and trunk are most commonly
involved, the tumors may  originate from any part of the body.
BFHs generally arise as slow-growing, painless, hyperkeratotic,
brownish-red solitary masses of <1-cm diameter that protrude
from the skin. In 10% of cases, the presence of more than two  lesions
has been reported.1
BFH constitutes a diagnostic dilemma because the lesions
share common clinical symptoms, radiological characteristics, and
histological features with benign and malignant lesions, such
as nonossifying ﬁbromas, giant cell tumors, ﬁbrous dysplasia,
aneurysmal bone cysts, osteoblastomas, eosinophilic granulomas,
chondrosarcomas, rhabdomyosarcomas, desmoid tumors, DFSPs,
and MFHs.4 Therefore, a deﬁnitive diagnosis of BFH should be made
by evaluating the patient’s symptoms, tumor location, radiological
characteristics, histopathological features, and immunohistochem-
ical staining results.
The  inclusion of aggressive ﬁbrohistiocytic tumoral lesions, such
as DFSP and MFH, in the differential diagnosis of deep-seated BFH is
of critical importance in planning the surgical approach and post-
operative patient management. The pivotal point in differentiating
between BFH and MFH  is the histopathological presence or absence
of pleomorphism and atypical mitotic activity. Both BFHs and DFSPs
can stem from the dermis and the subcutaneous tissues, but DFSPs
invade the subcutaneous tissues much more aggressively. BFHs are
composed histopathologically of various combinations of ﬁbrob-
lasts, Touton-type giant cells, and blood vessels, whereas DFSPs are
characterized by the storiform pattern of cellular arrangement and
by the absence of giant cells or xanthamatous cells. Moreover, an
increased rate of mitosis is evident. While the cells in BFHs exhibit
an intense staining pattern for factor XIIIa, they stain negatively
for CD34.5 However, the cells in DFSPs show a scattered staining
pattern for factor XIIIa, in contrast to intense staining for CD34.2
The treatment of choice for BFHs is wide resection of the tumor,
resulting in an excellent prognosis and a low recurrence rate. We
determined that wide excision proved to be adequate in prevent-
ing recurrence of the tumor, which conﬁrms results previously
reported in the literature. Wide excision is deﬁned as excision of
the mass with a conﬁdence margin of 1–2 cm;  however, consen-
sus has not been reached on this issue.4,5 Studies can be conducted
about adequate surgical margin with intraoperative frozen section.
However, the centers we work must have facilities required to do
this.
4. Conclusions
Our aim in this study was  to emphasize several issues. First,
immunohistochemical staining should be used in differentiating
between BFH and DFSP. Second, patients should undergo robust
scrutiny before the physician recommends radiotherapy. Lastly,
this study gave us the opportunity to present a negative result,
which has rarely been reported in other studies. We reported the
negative results to provide readers with robust data, and hope that
scientiﬁc transparency will improve as additional studies of this
type are published.Conﬂict of interest
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